未找到相关数据
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma.
被引：7
作者：
Eisenstat, D. D.
Nabors, L. B.
Mason, W. P.
Perry, J. R.
Shapiro, W. R.
Kavan, P.
Phuphanich, S.
Fu, Y.
Cong, X. J.
Shahidi, M.
Reardon, D. A.
机构：
[1] Univ Manitoba, CancerCare Manitoba, Winnipeg, MB, Canada
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
[4] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[5] St Josephs Hosp, Phoenix, AZ USA
[6] McGill Univ, Montreal, PQ, Canada
[7] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada
[8] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[9] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
[10] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
[11] Duke Univ, Med Ctr, Durham, NC USA
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2010
引用
收藏
页数：1
相关论文